A Methodology Study to Evaluate a Sitting Knee Measuring Device in Assessing Growth in Indian Children.

GlaxoSmithKline (GSK)

Status and phase

Completed

Phase 1

Conditions

Nutritional Status

Treatments

Dietary Supplement: Nutritional supplement with micronutrient

Dietary Supplement: Nutritional supplement without micronutrient

Study type

Interventional

Funder types

Industry

Identifiers

NCT02201225

201133

RH01817 (Other Identifier)

Details and patient eligibility

About

This methodology study will evaluate the sensitivity in using sitting knee digital caliper to measure changes in sitting knee length from over a 12-week study period amidst children in the age of 6 to 12 years in a community-based study in children ages 6 to 12 years who are receiving nutritional supplementation with micronutrients or without micronutrients.

Enrollment

109 patients

Sex

All

Ages

6 to 12 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Children (participants), both boys and girls, aged 6 to 12 years.
Participant height to be within the 25th to the 75th percentile of the standard height average in Indian children population
Participant will agree not to take any other nutritional supplements products during the study except the trial supplement

Exclusion criteria

Participant has any of the following medical conditions: Genetic disorders, chronic disease, metabolic disorders, endocrine disorders, immobilisation, and miscellaneous
Participant who in the past 6 months has used dietary or nutritional supplements with micronutrient fortification, or any form of dietary or herbal supplement intended to increase micronutrient intake, at a frequency of greater than 3-4times per month.
Participant receiving any supplements (such as calcium, iron and/or multivitamin at the time of screening).
Children (Participant) in Care are not allowed to participate in the study.
Allergy/Intolerance: Known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
Health conditions that would affect food metabolism including the following food allergies, kidney disease, liver disease, and/or gastrointestinal diseases (e.g. irritable bowel syndrome, celiac disease, peptic ulcers).
Use of concomitant medications that, in the opinion of the Principal Investigator (PI), might interfere with the outcome of the study or increases the risk of the participant, including corticosteroids (systemic or inhaled) and any medication for any behaviour-related disorders and/or stimulants.
Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any medical disorder, including history of alcohol or substance abuse, that would make the participant unlikely to fully complete the study or any condition that presents undue risk from the study product or procedures in the opinion of the PI/medical examiner.
Clinical Study/Experimental Medication: Participation in another clinical study or receipt of an investigational drug within 30 days of the screening visit.
Personnel: Currently, the participant's parents/legal guardian is an employee of the Sponsor or the study or members of their immediate family.